# Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach

Source: https://onco.cc/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/  
OnCo record `paper-bareche-tnbc-microenvironment-jnci-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Across 1,512 triple-negative tumours each molecular subtype had its own immune landscape: the immunomodulatory type is fully inflamed and suited to checkpoint drugs, while basal-like, LAR and mesenchymal tumours are immune-cold with the T cells kept at the margin.

## Summary

Tumour microenvironment heterogeneity was investigated within each TNBC molecular subtype, including immune infiltrate localisation and composition and expression of targetable immune pathways, in public transcriptomic and genomic datasets totalling 1,512 samples. Each subtype exhibited distinct profiles of immune, vascularisation, stroma and metabolism processes. The immunomodulatory subtype had the highest adaptive immune signatures and a fully inflamed spatial pattern; most mesenchymal stem-like and LAR tumours were immunosuppressive with high stromal signatures; basal-like, LAR and mesenchymal subtypes showed an immune-cold, margin-restricted phenotype. Tumours with high chromosomal instability and copy-number loss on 5q and 15q, including MHC-related genes, showed reduced cytotoxic activity as a plausible immune escape mechanism.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: JNCI: Journal of the National Cancer Institute
- Year: 2020
- DOI: 10.1093/jnci/djz208
- Authors: Bareche Y, Buisseret L, Gruosso T, et al.
- Findings: Immunomodulatory subtype: highest adaptive immune signatures, fully inflamed pattern.; Basal-like, LAR and mesenchymal: immune-cold, margin-restricted; MSL and LAR immunosuppressive stroma.; 5q and 15q loss including MHC genes reduces cytotoxic activity.
- What it means: It links the Lehmann subtypes to the spatial immune classes of Gruosso and gives a rationale for pairing checkpoint inhibitors with the immunomodulatory subtype and stromal or metabolic agents with the cold ones.
- Caveats: In silico deconvolution of public datasets; no prospective immunotherapy outcome data.; Spatial patterns were inferred, not measured, in most samples.

## Sources

- Bareche et al., JNCI 2020: tumour microenvironment heterogeneity across 1,512 TNBC samples: https://doi.org/10.1093/jnci/djz208
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31665482/

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- institutions: [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/), [Cold tumours: immune deserts and exclusion](https://onco.cc/pathways/immune-desert-exclusion/), [Tumour microenvironment (TME)](https://onco.cc/pathways/tumor-microenvironment/)
- terms: [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)
- journals: [JNCI: Journal of the National Cancer Institute](https://onco.cc/journals/jnci/)

---
JSON: https://onco.cc/api/v1/entities/paper-bareche-tnbc-microenvironment-jnci-2020.json